{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49","value":"31100"},{"groupId":"OG001","spread":"63","value":"22840"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Total elranatamab concentrations (C4D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47","value":"37960"},{"groupId":"OG001","spread":"77","value":"29880"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Total elranatamab concentrations (C7D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89","value":"19090"},{"groupId":"OG001","spread":"114","value":"16170"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Free elranatamab concentrations (C4D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"81","value":"32830"},{"groupId":"OG001","spread":"49","value":"29880"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Free elranatamab concentrations (C7D1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Total and free concentrations of Elranatamab on Cycle 4 Day 1 (C4D1) and Cycle 7 Day 1 (C7D1) were reported in this outcome measure.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Cohort A"},{"description":"BCMA-exposed participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG001","title":"Cohort B"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic (PK) analysis set was a subset of safety analysis set and included participants who had at least one post dose concentration measurement. Here, \"Overall Number of Participants Analyzed\" signifies maximum participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 4 and Pre-dose on Day 1 of Cycle 7","title":"Serum Concentration of Elranatamab","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}